It will be interesting to determine whether mammary-enriched ELF5, STAT5, NFIB, and GR are also recruited in these super-enhancers and whether differential molecular recruitment to super-enhancers determines the different breast cancer subtypes. This evidence concerns the gene ELF5 and breast carcinoma.